About GliaCure

GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.

GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »

Latest News



GliaCure President presents at ADDF, Society for Neuroscience conferences

On October 6 GliaCure President Phil Haydon presented an invited talk at the ADDF’s 16th International Conference on Alzheimer’s Drug Discovery in New Jersey. In his presentation, titled, “The P2Y6 receptor as a therapeutic target for Alzheimer’s disease”, Phil outlined the strategy underlying the company’s approach to development of a therapy to halt disease progression...more »

Skip to toolbar